Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its second quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 6, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) using conference ID number and event passcode 3647053. To access the webcast, please visit the Investors & Media section of Ironwood’s website at www.ironwoodpharma.com.
The call will be available for replay via telephone starting Thursday, August 6, 2026, at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, August 20, 2026. To listen to the replay, dial (800) 770-2030 (U.S. and Canada) using conference ID number 3647053. Following the call, a replay of the webcast will be available on the Investors & Media section of the Company’s website at: Ironwood Pharmaceuticals, Inc. - Events & Presentations.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs.
Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland.
We routinely post information that may be important to investors on our website at http://www.ironwoodpharma.com. In addition, follow us on X and on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260730260876/en/